Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 27 January 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Zydus Lifesciences reported Q3 FY25 net profit of ₹87.22 crores, up 32% year-on-year, driven by strong domestic sales growth of 69.9%. The company highlighted robust performance in its domestic formulation segment and improved gross margins. Management indicated sustained momentum in key therapeutic areas and plans to expand market reach in the coming quarters.

📄 View Original Announcement (PDF)

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,01,800.69 Cr P/E: 22.5

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ZYDUSLIFE — Free

Free account · 2 AI queries/day